Oncology
and Radiotherapy©
18(8) 2024: 001-008 • RESEARCH ARTICLE

An investigation on the effects of thoracic organ transplantation with respect to pre-transplant malignancies

Sanjay Bhatnagar[1], Debrup Banerjee[2], Shantanu Kulkarni[3], Upendra Sharma Udayashankar Sulibele[4], Shikhar Gupta[5], Geetika M. Patel[6]

[1] Centre of Research Impact and Outcome, Chitkara University, Rajpura, Punjab, India
[2] Department of UGDX, ATLAS SkillTech University, Mumbai, Maharashtra, India
[3] Department of Emergency Medicine, Krishna Institute of Medical Sciences, Maharashtra, India
[4] Department of Biotech and Genetics, School of Sciences, Jain (Deemed to be University), Bangalore, India
[5] Chitkara Centre for Research and Development, Chitkara University, Himachal Pradesh, India
[6] Department of Community Medicine, Parul University, Vadodara, Gujarat, India

ABSTRACT

Background: Organ transplantation is generally contraindicated by Pre-Transplant Malignancy (PTM). One healthy lung from a deceased donor is often used to replace one that is diseased, failing, or otherwise damaged in a lung transplant. Only patients who have not shown significant improvement after receiving standard medical care are acceptable for a lung transplant.

Objective: The study's objective was to observe the effects of thoracic organ transplantation in connection to PTM.

Methods: In our study, collected 13,603 adult patients had lung transplants. Secondary stratification was based on tumor kind, with primary stratification determined by PTM. Mortality was assessed using multivariable Cox proportional hazards regression models and matched cohorts (2:1).

Results: PTM was found in 7.4% of the 640 lung transplant patients. Average annual examination of lung transplantation patients with PTM found that their subsistence amounts at 90-days, 3 years, and 7 years were similar to those of patients without PTM ($p<0.05$). Even after risk adjustment, these results remained. No tumor type was linked to a higher mortality rate in lung transplantation patients. Analyses of identical groups in lung transplantation patients showed equivalent results. We investigate the survival rate, risk factors, and Lungs Allocation Score (LAS) of PTM patients.

Conclusion: This extensive investigation examining the impact of PTM discovered that the incidence of PTM was 5.2% in lung transplantation. PTM does not, in general, increase mortality in any group. Consequently, carefully chosen PTM patients shouldn't be denied lung transplantation.

Keywords: Pre-Transplant Malignancies (PTM), Lung Transplantation (LT), tumor, multivariable regression model

Address for correspondence:

Sanjay Bhatnagar

Centre of Research Impact and Outcome, Chitkara University, Rajpura, Punjab, India

E-mail: sanjay.bhatnagar.orp@chitkara.edu.in

Word count: 4155 **Tables:** 10 **Figures:** 03 **References:** 18

Received: 14 August, 2024, Manuscript No. OAR-24-145473
Editor Assigned: 17 August, 2024, Pre-QC No. OAR-24-145473(PQ)
Reviewed: 01 September, 2024, QC No. OAR-24-145473(Q)
Revised: 08 September, 2024, Manuscript No. OAR-24-145473(R)
Published: 16 September, 2024, Invoice No. J-145473

INTRODUCTION

Patients with PTM have traditionally been excluded from or limited in their eligibility for transplant due to immunosuppression required following solid organ transplantation. To prevent allograft rejection and consequent death, individuals with PTMs are often prescribed immunosuppressive drugs. Furthermore, immunosuppressive therapy has been shown to increase the likelihood of developing de novo malignancies in transplant recipients. Skin, lung, and prostate cancer development may be more likely in people who have had lung transplants [1]. The most popular initiatives for choosing PTM patients for SOT were extrapolated from advice given to people who might get kidney transplants. Cancer treatment should be separated by at least two years from SOT. Breast ductal carcinoma in situation, a tumor with an extremely small or nonexistent likelihood of recurrence, was still recommended to wait two years before undergoing any further treatment. For cancers with a higher recurrence risk, even longer waiting periods of 2 years–5 years or longer were recommended, despite a lack of data to back such recommendations. Based on research from the IPITTR, 21% of transplant recipients with PTM reported a malignant recurrence in the 5-years following SOT, with higher rates in other high-risk malignancies. The previous recommendations were founded on this information [2]. Leukemia, various hematological malignancies, immunodeficiency syndromes, hemoglobinopathies, and metabolic diseases are just a few of the many potentially fatal problems that allogeneic HSCT can effectively cure in both children and adults. Increases in the success rate of allogeneic HSCT are expected as a result of developments in donor selection, cytotoxic drug conditioning, and supportive care. While HSCT might be lifesaving, treatment often leaves patients with a new set of health problems and the fear that their original sickness will return. Recurrences is the primary cause of therapeutic failure and death in individuals with susceptible haematopoiesis. Patients that have previously had a relapsed condition are more likely to suffer one. Primary disease accounts for 21% and 59% of mortality in the first and second 100 days after allogeneic HSCT, respectively [3]. The moral standard of equity must also be taken into account while weighing the possibility of a cancer recurrence following SOT, the patient's potential death, and the loss of the organ. To strike a fair balance between the efficient allocations of a limited commodity as well as the advantages of transplant for a specific patient with a PTM [4]. The study analyzed the risk factors

for developing cancer in a large group of LT patients in France using a generative probabilistic regression model developed by Fine and Gray [5]. Long-term outcomes for kidney transplant patients might be worsened by the presence of pre-TM, which also increase the risk of developing post-TM. Modern trends and effects in the population of patients had not been compared to individuals without a pre-TM in big database research [6]. The issue was particularly important for preventative approaches and encourages more research to create a tailored prevention strategy for every patient using risk factors and screening tools [7]. GVHD was more common and more severe when the gut flora was altered after an allogeneic donation of hematopoietic stem cells. Patients with hematological malignancies typically use antibiotics to treat febrile neutropenia prior to allogeneic HSCT, which may alter the faecal flora and increase the risk of graft-versus-host disease [8]. Distress was found to be associated with OS after allogeneic HSCT [9]. Adolescents with unresectable hepatic malignancies can undergo living donor organ transplants [10]. In myelofibrosis, spleen size and splenectomy might predict allo-HCT outcome. In the EBMT registry, they discovered that 1195 patients with myelofibrosis had stem-cell transplantation following fludarabine-busulfan or fludarabine-melphalan regimens between 2000 and 2017 [11]. The study's goal was to evaluate the clinical and financial costs associated with benevolent and malevolent skin lesions in Central Queensland kidney transplant recipients [12]. The use of allo-HCT to treat CP chronic myeloid leukemia has dropped dramatically since the discovery of TKI. The Severe Malignancies Convention of the EBMT carried out follow-up research [13]. Only a small amount of information was available at the time about how PTM influences outcomes following LT. The study's objective was to observe the effects of thoracic organ transplantation in connection to PTM.

The remaining portion of this study is structured as following: In Part 2, the materials and techniques are presented. The findings are given in Part 3. The 4th part contains the debate. Part 5 has the conclusion. Part 6 contains the limitation.

METHODOLOGY

Study collection

The study participants were all adult (18-years old) members who received a lung transplant.

Inclusion and exclusion criteria

- The analysis of the study comprised an evaluation of all relevant confounders, including transplant variables, patient information, as well as the donor information.
- Mortality at 90 days, 3 years, and 7 years were the main effects.
- Patients undergoing multi-visceral organ transplants retransplant patients, and patients without PTM data were not included in the analysis. Another criterion for classification was the existence of a specific type of PTM, such as Ml or Non-ml skin cancer, SOT, HM, MT, or other PTM.

LT patients were divided into subgroups for evaluation both prior to and after the implementation of the LAS.

Statistical analysis

A statistical test, as with the Mann-Whitney U test, or a nonparametric test, the student's t-test was utilized to make assessments between incessant factors. To further evaluate the relationships and changes throughout collections of categorical information, we also used the chi-square test and Fisher's exact test. Due to this fact, we used the Kaplan-Meier approach to assessment the likelihood of persistence. Death risk was estimated using MCPHRM for several parameters of interest. A first univariate analysis of covariates was conducted. Using a backward-stepwise strategy, we added related variables from the experimental evaluation ($p<0.20$), those with biological plausibility, and those that had initially disclosed importance to the model. Using a multi-step process that included Akaike's information criterion and the Lagrange multiplier test, the model with the most predictive variable was selected. Further to reduce the influence of confounding variables in assessing the impact of PTM, we used a 2:1 cohort matching strategy in conjunction with multivariable Cox models. As anticipated, a multivariate propensity model was built. It is assumed that everything has a normal distribution when using discriminant analysis to develop a propensity model. The assumption was not made in our analysis because we employed the logistic regression method. Two-to-one nearest-neighbor matching without replacement was utilized to construct the matched cohort based on the proposed propensity model. The L:1 matching method made it appear as though all data had been created at random, and further studies of this cohort were conducted using the several unmatched statistical methods we covered. Any $p<0.05$ remained kept to specify arithmetic implication. Standard deviations and interquartile ranges are shown with mean and median values. The CI surrounding the HR are also displayed. The statistical evaluation was done with STATA 11.2.

RESULT ANALYSIS

A total lung transplantation cohort of 13,603 individuals was generated during our investigation after exclusion criteria were used. 7,567 patients (or 54%) of the LT cohort had a mean age of 55 years ± 14 years. IPF (n=3,956) was the most typical reason for transplantation. In 640 cases, PTM was present. During the LAS era, 8,498 patients received transplants, and their average LAS score was 47 ± 18. A propensity score was generated using LR analysis, and 532 of 640 patients with PTM were matched with 263 healthy people, resulting in a total matching group of 1,895 individuals who had LT. The popular of the patients in this matched group were male, with a M age of 60 and an average SD of 11. After LAS, the average score increased to 4514 among the 1,449 patients participating in the study.

Table 1 compares patient characteristics and illnesses between those with and without PTM. It includes gender distribution, age, and various lung-related conditions.

The variables determining transplantation outcomes, including age, CMV positive, and donor features such human leukocyte antigen matching, are compared in Table 2.

The medical and lung capacity characteristics (e.g., mean pulmonary artery pressure, lung allocation score, ventilator support, and other relevant aspects) of donors with and without PTM are presented in Table 3.

Tab. 1. Patient characteristics

Factor	With PTM (n=640)	Without PTM (n=12,963)	p-Value
Male sex	408/640	7,163/12,963	0.6
Age, years	59.7 ± 10.8	52.5 ± 13.1	<.01
Cystic fibrosis	14/741	1,845/12,874	<.01
IPF	250/741	3,713/12,873	<.01
Another diagnosis	148/740	2,291/12,873	0.14
Pulmonary hypertension	10/742	317/12,875	0.07

Tab. 2. Donors and transplantation factors

Factor	With PTM (n=640)	Without PTM (n=12,963)	p-Value
Human leukocyte antigen matching	394/648	6,329/10,812	0.3
Age, years	34.5 ± 14.7	33.3 ± 14.1	0.02
Cytomegalovirus positive	475/737	7,789/12,807	0.04
Male sex	429/741	7,776/12,873	0.19
Bilateral LTx (Lung Transplant)	407/740	7,654/12,873	<0.01
Waiting list time, days	79	138	<0.01
Ischemic time, hours	5.0 ± 1.8	5.0 ± 1.7	0.75
Gender matching	513/740	8,805/12,873	0.65

Tab. 3. Medical and lung capacity characteristics

Factor	With PTM (n=640)	Without PTM (n=12,963)	p-Value
Mean PA pressure, mm Hg	24.5 ± 8.6	26.6 ± 12	<0.01
Lung Allocation Score	43.2 ± 14.3	43.8 ± 14.7	0.53
Ventilator support	49/640	528/12,963	<0.01
Heart output, liters/min	6.3 ± 2.3	6.4 ± 2.6	0.79
Transpulmonary gradient	15.8 ± 8.1	15.3 ± 10	<0.01
Physical vitality, liters	49.6 ± 17.1	58.7 ± 25	0.12

For the purpose to assess the frequency of outcomes with and without PTM, table 4 looks at the yearly focus on LT output, separated down into two age groups.

Tab. 4. LT Output

Factor	With PTM (n=640)	Without PTM (n=12,963)	p-Value
20-31	156/640	3,465/12,963	<0.01
≥ 49	268/640	3,124/12,963	<0.01
31-48	146/640	3,004/12,963	0.16
≤ 19	167/640	3,305/12,963	0.04

Similar variations in basic variables were found in the matched cohort after being stratified by PTM. Once more, White and hypertensive patients with PTM were more prevalent. In PTM patients, respiratory failure was not likely to be brought on by either IPF or cystic fibrosis. Receiving CMV-positive organs was more likely for PTM patients. In the matched cohort, neither before nor after LAS, the overall PTM incidence changed (Figure 1).

Figure 1 and table 5 depicts the patient's survival rate. Analysis of Kaplan-Meier survival times according to the presence of any cancer before transplantation. The 7-year mortality rate for LT patients with a PTM was greater than that for their equivalents without a PTM.



Fig. 1. The patient's survival rate

Tab. 5. Values of patient's survival rate

Survival Rate	PTM	No PTM
0	60	85
1	62	91
2	65	93
3	71	95
4	75	97
5	77	98
6	79	97
7	82	98

Figure 2 and table 6 depicts the risk factors in lung transplantation. Patients' risks of death from any cause and PTM are stratified separately. The 7-years death rates of males with PTM were significantly higher than those of individuals without PTM. This mortality gap remained even after adjusting for prostate cancer risk by excluding gastrointestinal malignancies. In contrast, there was no increased mortality risk in the subsequent 7-years for female patients diagnosed with PTM compared to female controls. The 7-years mortality rate for women with PTM was the same as that for those without PTM, even after adjusting for breast cancer.



Fig. 2. Risk factors in LT

Tab. 6. Values of LT

Time (years)	No cancer (%)	MI (%)	Non-MI (%)	SOT (%)	HM (%)	MT (%)	Other (%)
0	94	85	78	68	56	46	35
1	95	86	79	69	57	47	36
2	96	87	80	70	60	51	38
3	96	90	82	71	61	51	41
4	97	91	84	74	63	53	43
5	97	93	85	75	65	54	45
6	98	94	86	76	68	58	48
7	99	95	89	78	71	62	51

According to an initial analysis, PTM and no particular tumor type were linked to an increase in fatalities (Figures 1 and 2). PTM was not linked to a higher risk of mortality at 90 days, 3-years, or 7-years, according to an adjusted study. No subset of tumors was associated with a significantly higher mortality risk over any time period. All models showed that higher yearly center volume reduced mortality, while higher serum creatinine, older age, and the need for intensive care unit treatment prior to lung transplantation were all associated with a higher mortality rate. This section depicts the statistical analysis of MCPHRM.

Cancer-related factors

Table 7 looks at how various cancer types affect hazard ratios. p-values all over 0.05 imply that none of the variables have a significant effect, indicating that there is no substantial link between these cancer kinds and the hazard ratio.

Patient institute and medical factors

Factors pertaining to patient care and medical treatments are shown in table 8. While other parameters such as FEV1, ECMO, and ventilator support do not significantly affect increased hazard ratios, hospitalization, transpulmonary gradient, and inpatient care execute.

Tab. 7. Cancer related factor

Elements	MHR (95% CI)	P-value
No cancer	-	-
HM	1.13 (0.57-2.16)	0.75
Non-Ml skin cancer	1.11 (0.73-1.61)	0.65
Ml	0.99 (0.49-2.02)	<0.99
MT	1.15 (0.36-3.54)	0.83
Other	0.59 (0.22-1.38)	0.23

Tab. 8. Patient institute and medical factors

Elements	MHR (95% CI)	p-value
FEV1 per litre	0.99 (0.98-1.01)	0.89
Hospitalized	1.39 (1.16-1.64)	<0.02
TG	1.02 (1.02-1.04)	<0.01
ECMO support	1.30 (0.78-2.22)	0.38
ICU	1.90 (1.44-1.65)	<0.01
INO	0.78 (0.31-2.12)	0.62
Ventilator support	1.05 (0.83-1.37)	0.8
LAS era	0.99 (0.84-1.14)	0.69

Donor and transplantation factors

Table 9 examines parameters associated to transplantation and donors. Factors such as ischemia time per hour and cigarette use do not significantly affect increased hazard ratios; however, diabetes and racial matching provide.

Tab. 9. Donor and transplantation factors

Factors	Multivariate Hazard Ratio (95% CI)	p-value
CU	1.13 (0.98-1.32)	0.13
BPR	1.33 (0.86-2.09)	0.16
IU	0.95 (0.87-1.05)	0.19
BLT	0.88 (0.78-0.97)	0.03
Diabetes	1.39 (1.16-1.71)	<0.01
RM	0.86 (0.78-0.96)	<0.01
ITH	0.99 (0.96-1.03)	0.26
APY	0.99 (0.98-1.01)	0.45
IAHL	0.95 (0.88-1.07)	0.32

LT output factors

Table 10 appears at the output variables related to LT. There is a high statistical correlation between the various output ranges (32-46, ≥ 47, 19-31) and patient outcomes in LT. These relationships are statistically significant.

Tab. 10. LT output factors

Focus on LT Output	Multivariate Hazard Ratio (95% CI)	p-value
32-46	0.73 (0.64-0.86)	<0.01
≤ 18	-	-
≥ 47	0.72 (0.63-0.84)	<0.01
19-31	0.78 (0.70-0.91)	<0.01

Figure 3 depicts the LAS score. PTM was linked to the same level of survival both before and after the commencement of the LAS, apart from the fact that it became more common after LAS (Figure 3). Similarly to the overall lung transplantation cohort, PTM, and specific tumor types had no discernible impact on survival at any time. Furthermore, PTM was never linked to a rise in mortality before or after the development of the LAS. Even after adjustments were made, PTM and other types of tumors were still poor predictors of mortality. ICU admission before lung transplantation is the only significant health risk for mortality observed throughout all models.



Fig. 3. LAS sco

DISCUSSION

Due to the high risk of tumor recurrence during post-transplant immunosuppression, patients whose cancer was caused by a pre-existing condition are typically not good candidates for LT. Although the LAS has led to a rise in the number of PTM patients receiving lung transplants, the results of these procedures on overall mortality and the reasons for death are not yet understood. We found no association between PTM and increased mortality in either an adjusted or unadjusted analysis of 13,603 individuals who had had lung transplantation. There was an increase in PTM usage beginning with the LAS, but no change in PTM mortality throughout this time. A cohort study of people who had undergone lung transplantation and shared the same propensity scores provided further evidence for these conclusions. The literature on lung transplantation has recurrence rates anywhere from 0% to 56%; again, all recurrences occur in the first 7-years after the transplant. All immunosuppressed individuals who undergo transplantation run the risk of de novo tumor development in addition to the recurrence risk related to PTM [14]. Estimate that the standardized incidence ratio for cancer following solid-organ donation is 2.10 when compared to the general population [15]. Yet, 14% of lung transplant recipients without PTM and 13% of OHT recipients who received new organs develop cancer within 7-years of receiving them. The impact of PTM on survival is looked at in this research, although the issue of de novo cancer growth or recurrence is not addressed. In addition to the disease itself, the immunosuppressive regimen and how it may differ between individuals are explored in the research on thoracic PTM. Only 1 out of 7 patients with PTM who had OHT experienced a relapse of their condition, proving that conventional immunosuppressive therapies could keep grafts functioning [16]. In their study of pediatric lung transplantation for PTM patients, just one child (5%) encountered a modification to their post-transplant immunosuppressive treatment, and no patients relapsed. Although we did not look at the specific immunosuppressive regimens of the participants in this investigation, our findings suggest that PTM patients do not require personalized immunosuppressive medication [17]. Several research key differences between PTM patients and those who do not have the condition. Some of these differences are intuitive, such as the generally higher age at diagnosis in PTM patients related to the overall populace, while others have been a bit of a surprise. Donors in lung transplantation cohorts, both PTM and non-PTM, spanned a wide age range [18]. At least one group also had statistically significant changes in other donor criteria, but these variations were small and not likely to have any practical implications in clinical practice. Surprisingly, even though lung transplantation patients often need larger doses of immunosuppression than their OHT counterparts, hematologic malignancies were never linked to an elevated risk in lung transplantation patients. Cancer, bronchioloalveolar carcinoma, as well as medulloblastoma, have all been linked to malignancy-associated fatalities in lung transplantation patients. It is difficult to conduct a careful analysis of tumor-associated risk because the majority of the literature consists of case reports or small series. However, this does not explain all variations in the hazard difference reported in lung transplantation patients in this study. This hazard difference may be due to intrinsic mortality disparities across the groups as well as variations in selection criteria.

CONCLUSION

A separate analysis provides a brief PTM affects outcomes after lung transplantation and found no association between PTM and poorer survival. Hematologic malignancies were connected with a higher transience hazard in lung transplantation patients, according to secondary tumor type categorization. A LAS-based subgroup analysis finds no discernible impact on the results. These results were confirmed by analyzing a cohort of LT patients who were selected using a propensity score matching algorithm. It is necessary to learn more about the role of immunosuppressive regimes, tumor persistence, and "newly arising" tumor growth. Lung transplantation can be carried out with comparable results on carefully chosen PTM patients. To better understand PTM and the many PTM that can arise, future research should look at the availability of detailed institutional data on these aspects.

LIMITATION

There are several restrictions to this study. First, statistics on disease-free survival before transplantation and other clinically pertinent PTM information. Second, because these factors and their associations with mortality outcomes were not examined in our investigation, we are unable to comment on them or their associations with recurrence, de novo tumor development, or immune-suppression data. Moreover, the suitability of the propensity score for our patient population is crucial to the outcome of our matched cohort trial. Because not all patients would meet the criteria for inclusion in this analysis, a selection bias is generated. Finally, although the data set contains a large number of variables that can be examined, it is still possible that certain variables with significant influence were overlooked. While conducting this research, we had the incorrect assumption that any coding mistakes or gaps in the data would be completely coincidental and hence

generate no bias whatsoever. If this assumption is incorrect, relative bias may develop.

REFERENCES

1. Rudasill SE, Iyengar A, Sanaiha Y, Khoury H, Mardock AL, et al. Pretransplant malignancy among lung transplant recipients in the modern era. Surgery. 2019;165:1228-1233.
2. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, et al. Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant. 2021;21:460-474.
3. Brice L, McErlean G, Donovan C, Tapp C, Gilroy N, et al. Fear of cancer recurrence following allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancy: a cross-sectional study. Eur J Oncol Nurs. 2020;49:101845.
4. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant. 2021;21:475-483.
5. Altieri M, Seree O, Lobbedez T, Segol P, Abergel A, et al. Risk factors of de novo malignancies after liver transplantation: A French national study on 11004 adult patients. Clin Res Hepatol Gastroenterol. 2021;45:101514.
6. Livingston-Rosanoff D, Foley DP, Leverson G, Wilke LG. Impact of pre-transplant malignancy on outcomes after kidney transplantation: United Network for Organ Sharing database analysis. J Am Coll Surg. 2019;229:568-579.
7. Turshudzhyan A. Post-renal transplant malignancies: Opportunities for prevention and early screening. Cancer Treat Res Commun. 2021;26:100283.
8. Lee MW, Yeon SH, Heo BY, Kwon J, Ryu H, et al. Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies. Hematology. 2021;26:96-102.
9. Wang SM, Park SS, Park SH, Kim NY, Kang DW, et al. Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study. Sci Rep. 2020;10:1-10.
10. Pire A, Tambucci R, De Magnée C, Sokal E, Stephen X, et al. Living donor liver transplantation for hepatic malignancies in children. Pediatr Transplant. 2021;25.
11. Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the Chronic Malignancies Working Party on behalf of European Society for Blood and Marrow Transplantation (EBMT). Am J Hematol. 2021;96:69-79.
12. The Z, Lam AK, Pham T, Ng SK, Steel JC, et al. Clinical and economic burden of benign and malignant skin lesions in renal transplant recipients. Intern Med J. 2023;53:2042-2049.
13. Chalandon Y, Bianchi G, Gras L, Koster L, Apperley J, et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2023;98:112-121.
14. Alabdaljabar MS, Muhsen IN, Knight JM, Syrjala KL, Hashmi SK. Free of malignancy but not of fears: a closer look at Damocles syndrome in survivors of hematologic malignancies. Blood Rev. 2021;48:100783.
15. Hart A, Pfeiffer RM, Morawski BM, Lynch CF, Zeng Y, et al. Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis. Am J Transplant. 2023;23:257-264.
16. de Boer SE, Sanders JS, Bemelman FJ, Betjes MG, Burgerhof JG, et al. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. BMC Nephrol. 2021;22:208.
17. Greenberg D. Cancer Risk in the Adult Solid Organ Transplant Recipient. In: Prim Care Solid Organ Transpl Recip. 2020:231-252.
18. Ramos KJ, Kapnadak SG, Bradford MC, Somayaji R, Morrell ED, et al. Underweight patients with cystic fibrosis have acceptable survival following lung transplantation: a United Network for Organ Sharing registry study. Chest. 2020;157:898-906.